Background: Time interval between neoadjuvant (combined) chemotherapy and radiation (nCRT) and surgery has been linked to pathologic response rates and outcomes in patients with various solid cancers. The optimal timing between nCRT and esophagectomy in patients with esophageal squamous cell carcinoma (SCC), however, is not known. Our aim was to analyze the relation between elapsed time from completion of nCRT to esophagectomy and postsurgical mortality and overall survival.
Methods: We reviewed the National Cancer Database for patients with SCC (n = 1,244) of the esophagus diagnosed between 2003 and 2011 who were treated with nCRT followed by esophagectomy within 26 weeks after completion of nCRT.
Results: Thirty-day mortality was 5.6% and 90-day mortality was 11.1%. The duration of post-nCRT interval was not a predictor of 30-day and 90-day postoperative mortality in multivariate models, but 30-day postoperative mortality was predictable based on increasing Charlson-Deyo comorbidities (adjusted odds ratio [aOR] 1.77, P = .054) and improved in academic institutions (aOR 0.66, P = .005). Similar findings were found for 90-day mortality (comorbidity index aOR 1.58, P = .046) and for treatment at an academic facility (0.82, P = .062). In a multivariate survival analysis, the duration of the post-nCRT interval was not found to be a predictor of overall survival (P = .769), whereas increasing age (hazard ratio [HR] 1.02, P = .005), increasing comorbidity score (HR 1.38, P = .005), treatment at an academic hospital (HR 0.84, P = .001), and post-treatment nodal status (HR 1.73, P < .001) were predictors.
Conclusion: Perioperative mortality and overall survival are not affected by the time interval between completion of nCRT and esophagectomy among patients with SCC histology.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.surg.2018.04.026 | DOI Listing |
Int J Radiat Oncol Biol Phys
January 2025
Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address:
Background: Neoadjuvant chemoradiotherapy (nCRT) followed by surgical resection is the current standard of care for oesophageal cancer (EC) patients. This treatment is associated with a variety of complications, with pneumonia being the most common. We hypothesize that proton radiotherapy (PRT) can significantly reduce the incidence of pneumonia compared to photon radiotherapy (PhRT).
View Article and Find Full Text PDFBMC Cancer
January 2025
Department of Minimally Invasive Esophageal Surgery, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Background: In this study, we retrospectively examined the prognostic significance of the pathological status of esophageal squamous cell carcinoma (ESCC) patients following neoadjuvant chemoradiotherapy (NCRT) and surgery.
Methods: Data of patients with cT2-4aN0-3 stage ESCC who underwent NCRT and esophagectomy during 2014-2022 were reviewed retrospectively. Survival differences were compared according to revised TN (rTN) stage (ypT0N0, ypT + N0, ypT0N+, and ypT + N+) using univariate and Cox regression analyses.
Asian J Surg
December 2024
Department of Cardio-thoracic Surgery, The Tibet Autonomous Region People's Hospital, China.
Backgroud: Neoadjuvant therapy followed by surgery has been proved to improve the survival of patients with ESCC, and neoadjuvant chemoradiotherapy (nCRT) is the standard of care in most areas of the world. However, multimodality therapy including radiation therapy is actually limited in the current treatment of esophageal cancer in Tibet. The role of neoadjuvant immunotherapy in resectable esophageal cancer has been assessed in multiple phase II clinical trials, but there's lack of evidence of applying neoadjuvant immunotherapy plus chemotherapy in Tibetan residents.
View Article and Find Full Text PDFZhonghua Zhong Liu Za Zhi
November 2024
Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou310022, China.
To compare the clinical efficacy of neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemo-immunotherapy (nCIT) for locally advanced esophageal squamous cell carcinoma (ESCC). Clinical data of patients who received nCRT or nCIT followed by esophagectomy for locally advanced ESCC between January 2010 and December 2022 were retrospectively collected from Zhejiang Cancer Hospital, with 155 patients in the nCRT group and 470 patients in the nCIT group. Propensity score matching (PSM) was performed in the two groups.
View Article and Find Full Text PDFPLoS One
November 2024
Department of Gastrointestinal Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Background: There is controversy about the benefit of administering adjuvant therapy to esophageal cancer (EC) patients after preoperative neoadjuvant therapy and surgical treatment. This study aims to investigate the clinical benefit of postoperative adjuvant therapy in EC patients with neoadjuvant therapy and surgery.
Materials And Methods: The study included EC patients diagnosed from 2007 to 2020 in the Surveillance, Epidemiology, and End Results (SEER) database.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!